Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page


Lack of absorption of extended-release pramipexole in a patient with early parkinson�?�??�?´s disease

Alberto Villarejo, Gema Lizcano, ?lvaro S?nchez-Ferro, Eduardo de Pablo-Fernandez

Pramipexole is a nonergot dopamine agonist indicated for treating Parkinson’s disease (PD) and restless legs syndrome. Pramipexole extended release (ER) is a recently developed once-daily formulation which has demonstrated noninferiority compared with pramipexole immediate release (IR) in the treatment of early [1] and advanced PD [2]. Compared with the immediate release (IR) formulation, the ER formulation offers some advantages, including the potential for improved compliance owing to its simple once-daily dosing regimen and steadier plasma levels over 24 h [3]. According to data from clinical trials, both formulations have a similar digestive absorption with a bioavailability of more than 90%, and the overnight switch from pramipexole IR three times a day to pramipexole ER once daily at unchanged dosage in PD patients has been shown to be successful in more than 80% of patients, with minor adjustments needed in the other patients [4]. Here we report the case of a patient with mild PD, unsuccessfully treated with pramipexole ER due to lack of digestive absorption of the drug.